Conference Track

Early Breast Cancer: Chemotherapy and Targeted Agents

Source: CCO Independent Conference Coverage of the CCO Independent Conference Coverage of the 2007 San Antonio Breast Cancer Symposium*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Capsule Summaries

Denosumab Increases Bone Mineral Density in Postmenopausal Women Receiving AI Therapy for Nonmetastatic Breast Cancer
Addition of Capecitabine to Docetaxel in Neoadjuvant Regimens Improves Response Only in Patients With Stage T4 Breast Cancer
No Cardiotoxicity Concerns When Bevacizumab Administered With Dose-Dense Doxorubicin/Cyclophosphamide and Nab-Paclitaxel
Limited Predictive Value of Polysomy 17 in Patients With Breast Cancer Treated With Anthracycline-Based Chemotherapy and Trastuzumab
Long-term Data Support Use of Docetaxel/Cyclophosphamide as NonAnthracycline Adjuvant Regimen in Breast Cancer
High-Dose Chemotherapy Regimens Combined with Autologous Stem Cell Transplant Offers No Significant Survival Benefits Compared With Standard-Dose Regimens
Recurrence Score Assay Predicts Adjuvant Therapy Benefit in Women With Node-Positive, ER-Positive Breast Cancer
Anthracycline Benefit Observed Only With Topoisomerase IIa Amplification in Patients With HER2-Positive Breast Cancer
Data From PACS-04 Indicate That Adjuvant Trastuzumab Confers No DFS Benefit Following Adjuvant Chemotherapy and Radiotherapy
Preliminary Data Demonstrate Bevacizumab Can Be Safely Added to Anthracycline-Containing Adjuvant Therapy in Node-Positive Breast Cancer
DFS Benefit of Adjuvant Trastuzumab in HER2-Positive Breast Cancer Independent of HER2 Assessment Method, Ratio, or Gene Copy Number

Expert Analysis

Early Breast Cancer: Chemotherapy and Targeted Agents

Faculty:

Howard A. Burris III, MD
William J. Gradishar, MD, FACP
Edith A. Perez, MD

Learning Objectives

Upon completion of this activity, participants should be able to:

Discuss the use of genetic signature assays to determine which breast cancer patients might benefit from specific therapeutic modalities
Cite the use of anthracyclines as adjuvant treatment for breast cancer
Describe the role of biologic and targeted agents in the treatment of breast cancer

CREDIT INFORMATION

Release Date: 02/25/08

Expiration Date: 02/24/09

Physicians: maximum of 1.25 AMA PRA Category 1 Credits™

Registered Nurses: 1.2 Nursing contact hours

Pharmacists: 1.2 contact hours (0.12 CEUs)

Status: Please log in to view status

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.